Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia
Donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell therapy led to complete responses in 18 of 20 patients with relapsed or refractory (r/r) T-cell acute lymphoblastic leukemia (ALL), a first-in-human clinical trial showed. After a median follow-up of 6.3 months, 15 of the 18 responding patients remained in remission, and seven patients had undergone stem-cell transplantation […]
Slow Going With CAR T-Cell Therapy for Solid Tumors
Almost 4 years after the first chimeric antigen receptor (CAR) T-cell therapies received FDA approval, the transformative impact of the treatment on refractory hematologic malignancies has yet to translate into the field of solid tumors. The increased molecular complexity of solid tumors and lack of good antigen targets have coalesced into a formidable roadblock for […]
Potential new CAR-T cell therapy for multiple myeloma
Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. Their findings were published on Friday, June 24, in The Lancet. “CAR-T cell therapy is a type of immunotherapy that involves harnessing the power of a person’s own immune system by engineering […]